✦ LIBER ✦

A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of a far infrared-emitting sericite belt in patients with primary dysmenorrhea

✍ Scribed by Chae Hyeong Lee; Ju-Won Roh; Chi-Yeon Lim; Jin Hwa Hong; Jae Kwan Lee; Eung Gi Min

Book ID: 116394800
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 245 KB
Volume: 19
Category: Article
ISSN: 0965-2299
DOI: 10.1016/j.ctim.2011.06.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of adalimumab in pat

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial

✍ Désirée van der Heijde; Alan Kivitz; Michael H. Schiff; Joachim Sieper; Ben A. C 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 2 views

Safety and efficacy of esreboxetine in p

Safety and efficacy of esreboxetine in patients with fibromyalgia: A fourteen-week, randomized, double-blind, placebo-controlled, multicenter clinical trial

✍ Lesley M. Arnold; Ian Hirsch; Paul Sanders; Amanda Ellis; Bernadette Hughes 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB

A randomized, double-blind, multicenter,

A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia

✍ Hiroyoshi Ohta, Hiroshi Oka, Chie Usui, Masayuki Ohkura, Makoto Suzuki, Kusuki N 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 370 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain

✍ Michael C. Rowbotham; W. Rachel Duan; James Thomas; Wolfram Nothaft; Misha-Miros 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 236 KB

Rituximab in patients with primary progr

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro

A multicenter, randomized, placebo-contr

A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes

✍ E. J. Rhee; W. Y. Lee; K. H. Yoon; S. J. Yoo; I. K. Lee; S. H. Baik; Y. K. Kim; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 531 KB